Free Trial
NASDAQ:ACLX

Arcellx Q1 2025 Earnings Report

Arcellx logo
$63.92 -1.29 (-1.98%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$63.82 -0.11 (-0.16%)
As of 05/23/2025 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcellx EPS Results

Actual EPS
-$1.13
Consensus EPS
-$0.84
Beat/Miss
Missed by -$0.29
One Year Ago EPS
N/A

Arcellx Revenue Results

Actual Revenue
$8.13 million
Expected Revenue
$19.51 million
Beat/Miss
Missed by -$11.38 million
YoY Revenue Growth
N/A

Arcellx Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Arcellx Earnings Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
FY2025 EPS Estimates for Arcellx Cut by Cantor Fitzgerald
See More Arcellx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arcellx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcellx and other key companies, straight to your email.

About Arcellx

Arcellx (NASDAQ:ACLX), together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

View Arcellx Profile

More Earnings Resources from MarketBeat